<?xml version='1.0' encoding='utf-8'?>
<document id="9314612"><sentence text="Pharmacokinetic interactions with felbamate. In vitro-in vivo correlation."><entity charOffset="34-43" id="DDI-PubMed.9314612.s1.e0" text="felbamate" /></sentence><sentence text="This article provides an analysis of the degree of agreement between in vivo interaction studies performed in patients with epilepsy and healthy individuals, and in vitro studies which identified the cytochromes P450 (CYP) inhibited by felbamate and those involved in its metabolism"><entity charOffset="236-245" id="DDI-PubMed.9314612.s2.e0" text="felbamate" /></sentence><sentence text=" In vitro studies show that felbamate is a substrate for CYP3A4 and CYP2E1"><entity charOffset="28-37" id="DDI-PubMed.9314612.s3.e0" text="felbamate" /></sentence><sentence text=" Compounds which induce CYP3A4 (e" /><sentence text="g" /><sentence text=" carbamazepine, phenytoin and phenobarbital) increase felbamate clearance"><entity charOffset="1-14" id="DDI-PubMed.9314612.s6.e0" text="carbamazepine" /><entity charOffset="16-25" id="DDI-PubMed.9314612.s6.e1" text="phenytoin" /><entity charOffset="54-63" id="DDI-PubMed.9314612.s6.e2" text="felbamate" /><pair ddi="false" e1="DDI-PubMed.9314612.s6.e0" e2="DDI-PubMed.9314612.s6.e0" /><pair ddi="false" e1="DDI-PubMed.9314612.s6.e0" e2="DDI-PubMed.9314612.s6.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s6.e0" e2="DDI-PubMed.9314612.s6.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s6.e1" e2="DDI-PubMed.9314612.s6.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s6.e1" e2="DDI-PubMed.9314612.s6.e2" /></sentence><sentence text=" However, the CYP3A4 inhibitors gestodene, ethinyl estradiol and erythromycin have little or no effect on felbamate trough plasma concentrations, consistent with the fact that the pathway is relatively minor for felbamate under normal (non-induced) conditions"><entity charOffset="43-60" id="DDI-PubMed.9314612.s7.e0" text="ethinyl estradiol" /><entity charOffset="65-77" id="DDI-PubMed.9314612.s7.e1" text="erythromycin" /><entity charOffset="106-115" id="DDI-PubMed.9314612.s7.e2" text="felbamate" /><entity charOffset="212-221" id="DDI-PubMed.9314612.s7.e3" text="felbamate" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e0" e2="DDI-PubMed.9314612.s7.e0" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e0" e2="DDI-PubMed.9314612.s7.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e0" e2="DDI-PubMed.9314612.s7.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e0" e2="DDI-PubMed.9314612.s7.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e1" e2="DDI-PubMed.9314612.s7.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e1" e2="DDI-PubMed.9314612.s7.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e1" e2="DDI-PubMed.9314612.s7.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e2" e2="DDI-PubMed.9314612.s7.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s7.e2" e2="DDI-PubMed.9314612.s7.e3" /></sentence><sentence text=" Felbamate has been shown in vitro to inhibit CYP2C19, which would account for its effect on phenytoin clearance, and it had been postulated that this could be the mechanism underlying the reduced clearance of phenobarbital by felbamate"><entity charOffset="1-10" id="DDI-PubMed.9314612.s8.e0" text="Felbamate" /><entity charOffset="93-102" id="DDI-PubMed.9314612.s8.e1" text="phenytoin" /><entity charOffset="210-223" id="DDI-PubMed.9314612.s8.e2" text="phenobarbital" /><entity charOffset="227-236" id="DDI-PubMed.9314612.s8.e3" text="felbamate" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e0" e2="DDI-PubMed.9314612.s8.e0" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e0" e2="DDI-PubMed.9314612.s8.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e0" e2="DDI-PubMed.9314612.s8.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e0" e2="DDI-PubMed.9314612.s8.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e1" e2="DDI-PubMed.9314612.s8.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e1" e2="DDI-PubMed.9314612.s8.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e1" e2="DDI-PubMed.9314612.s8.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e2" e2="DDI-PubMed.9314612.s8.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s8.e2" e2="DDI-PubMed.9314612.s8.e3" /></sentence><sentence text=" Although not yet examined in vitro, felbamate appears to induce the activity of CYP3A4, which would account for it reducing plasma concentrations of carbamazepine or the progestin gestodene"><entity charOffset="37-46" id="DDI-PubMed.9314612.s9.e0" text="felbamate" /><entity charOffset="150-163" id="DDI-PubMed.9314612.s9.e1" text="carbamazepine" /><entity charOffset="171-190" id="DDI-PubMed.9314612.s9.e2" text="progestin gestodene" /><pair ddi="false" e1="DDI-PubMed.9314612.s9.e0" e2="DDI-PubMed.9314612.s9.e0" /><pair ddi="false" e1="DDI-PubMed.9314612.s9.e0" e2="DDI-PubMed.9314612.s9.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s9.e0" e2="DDI-PubMed.9314612.s9.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s9.e1" e2="DDI-PubMed.9314612.s9.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s9.e1" e2="DDI-PubMed.9314612.s9.e2" /></sentence><sentence text=" Interactions involving felbamate and non-CYP450-mediated metabolic pathways have also been addressed in clinical studies"><entity charOffset="24-33" id="DDI-PubMed.9314612.s10.e0" text="felbamate" /></sentence><sentence text=" The reduction in valproic acid (valproate sodium) clearance by felbamate is through the inhibition of beta-oxidation"><entity charOffset="18-31" id="DDI-PubMed.9314612.s11.e0" text="valproic acid" /><entity charOffset="33-49" id="DDI-PubMed.9314612.s11.e1" text="valproate sodium" /><entity charOffset="64-73" id="DDI-PubMed.9314612.s11.e2" text="felbamate" /><pair ddi="false" e1="DDI-PubMed.9314612.s11.e0" e2="DDI-PubMed.9314612.s11.e0" /><pair ddi="false" e1="DDI-PubMed.9314612.s11.e0" e2="DDI-PubMed.9314612.s11.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s11.e0" e2="DDI-PubMed.9314612.s11.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s11.e1" e2="DDI-PubMed.9314612.s11.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s11.e1" e2="DDI-PubMed.9314612.s11.e2" /></sentence><sentence text=" No clinically relevant pharmacokinetic interactions were noted between felbamate and lamotrigine, clonazepam, vigabatrin, nor the active monohydroxy metabolite of oxcarbazepine"><entity charOffset="72-81" id="DDI-PubMed.9314612.s12.e0" text="felbamate" /><entity charOffset="86-97" id="DDI-PubMed.9314612.s12.e1" text="lamotrigine" /><entity charOffset="99-109" id="DDI-PubMed.9314612.s12.e2" text="clonazepam" /><entity charOffset="111-121" id="DDI-PubMed.9314612.s12.e3" text="vigabatrin" /><entity charOffset="138-149" id="DDI-PubMed.9314612.s12.e4" text="monohydroxy" /><entity charOffset="164-177" id="DDI-PubMed.9314612.s12.e5" text="oxcarbazepine" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e0" e2="DDI-PubMed.9314612.s12.e0" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e0" e2="DDI-PubMed.9314612.s12.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e0" e2="DDI-PubMed.9314612.s12.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e0" e2="DDI-PubMed.9314612.s12.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e0" e2="DDI-PubMed.9314612.s12.e4" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e0" e2="DDI-PubMed.9314612.s12.e5" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e1" e2="DDI-PubMed.9314612.s12.e1" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e1" e2="DDI-PubMed.9314612.s12.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e1" e2="DDI-PubMed.9314612.s12.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e1" e2="DDI-PubMed.9314612.s12.e4" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e1" e2="DDI-PubMed.9314612.s12.e5" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e2" e2="DDI-PubMed.9314612.s12.e2" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e2" e2="DDI-PubMed.9314612.s12.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e2" e2="DDI-PubMed.9314612.s12.e4" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e2" e2="DDI-PubMed.9314612.s12.e5" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e3" e2="DDI-PubMed.9314612.s12.e3" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e3" e2="DDI-PubMed.9314612.s12.e4" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e3" e2="DDI-PubMed.9314612.s12.e5" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e4" e2="DDI-PubMed.9314612.s12.e4" /><pair ddi="false" e1="DDI-PubMed.9314612.s12.e4" e2="DDI-PubMed.9314612.s12.e5" /></sentence><sentence text=" Information on the mechanisms underlying felbamate's drug:drug interaction profile permits predictions to be made concerning the likelihood of interactions with other compounds" /><sentence text="" /></document>